PharmaMar to present findings to FDA's Pediatric Oncology Subcommittee
PharmaMar will present clinical data from Phase I and II studies examining Zepsyre’s effect on pediatric cancers and hematological disorders to the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration. Read More »
Alerts Sign-up